Trial · NCT03332589
Results by group47
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 47
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Intracranial Disease Overall Response Rate by RANO-BM | Monotherapy Safety Run-in: E6201 | Complete Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Combination Safety Run-in: E6201 Plus Dabrafenib | Complete Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Expansion: E6201 Plus Dabrafenib | Complete Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Monotherapy Safety Run-in: E6201 | Partial Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Combination Safety Run-in: E6201 Plus Dabrafenib | Partial Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Expansion: E6201 Plus Dabrafenib | Partial Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Monotherapy Safety Run-in: E6201 | Stable Disease | 2 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Combination Safety Run-in: E6201 Plus Dabrafenib | Stable Disease | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Expansion: E6201 Plus Dabrafenib | Stable Disease | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Monotherapy Safety Run-in: E6201 | Progressive Disease | 1 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Combination Safety Run-in: E6201 Plus Dabrafenib | Progressive Disease | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Expansion: E6201 Plus Dabrafenib | Progressive Disease | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Monotherapy Safety Run-in: E6201 | Not Evaluable | 1 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Combination Safety Run-in: E6201 Plus Dabrafenib | Not Evaluable | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RANO-BM | Expansion: E6201 Plus Dabrafenib | Not Evaluable | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RECIST 1.1 | Monotherapy Safety Run-in: E6201 | Complete Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RECIST 1.1 | Combination Safety Run-in: E6201 Plus Dabrafenib | Complete Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RECIST 1.1 | Expansion: E6201 Plus Dabrafenib | Complete Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RECIST 1.1 | Monotherapy Safety Run-in: E6201 | Partial Response | 0 | Participants | |
| Intracranial Disease Overall Response Rate by RECIST 1.1 | Combination Safety Run-in: E6201 Plus Dabrafenib | Partial Response | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03332589/results